Free Trial
NASDAQ:PTPI

Petros Pharmaceuticals 5/15/2023 Earnings Report

Petros Pharmaceuticals logo
$0.05 0.00 (-8.18%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Petros Pharmaceuticals EPS Results

Actual EPS
-$0.66
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Petros Pharmaceuticals Revenue Results

Actual Revenue
$2.52 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Petros Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Petros Pharmaceuticals' next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

Petros Pharmaceuticals Earnings Headlines

[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.
Petros Pharmaceuticals prices 40M shares at 24c in public offering
See More Petros Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Petros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Petros Pharmaceuticals and other key companies, straight to your email.

About Petros Pharmaceuticals

Petros Pharmaceuticals (NASDAQ:PTPI), a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

View Petros Pharmaceuticals Profile

More Earnings Resources from MarketBeat